Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose–response study and open-label extension study

por Wada, Takashi, Inagaki, Masaya, Yoshinari, Toru, Terata, Ryuji, Totsuka, Naoko, Gotou, Miki, Hashimoto, Gaia
Publicado 2020